🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

Artemisinin attenuates 3-nitropropionic acid-induced neurodegeneration via HMGB1/TLR4/NF-κB modulation in a rat model of huntington's disease.

PMID: 41865324 · DOI: 10.1007/s12272-026-01604-1 · Archives of pharmacal research, 2026 · Aya M Mustafa, Mustafa Mudhafar, Ali M Elgindy, Manar M Esmail, Ahmed M Atwa, Aya M Shaheen, Abdullah F Radwan, Nourhan
📄 Abstract

Huntington's disease (HD) is a progressive neurodegenerative disorder characterized by motor, cognitive, and behavioral impairments associated with striatal neuronal loss, for which effective symptom-attenuating therapies remain lacking. Artemisinin (ART), a natural sesquiterpene lactone with established antioxidant and anti-inflammatory actions, has recently gained attention as a potential neuroprotective agent. This study evaluated the therapeutic relevance of ART in a rat model of HD induced by 3-nitropropionic acid (3-NP). 3-NP administration caused severe behavioral deficits, including an 81.8% reduction in rearing and a 74.9% reduction in ambulation (p < 0.0001), a 63.7% decrease in novel object exploration, and a 53.5% decline in Morris water maze target quadrant time versus controls. Biochemically, 3-NP elevated HMGB1 (4.8-fold), TLR4 (6.8-fold), RIPK1 (6.4-fold), RIPK3 (5.2-fold), MLKL (5.5-fold), p38-MAPK (4.2-fold), NF-κB (2.1-fold), and TNF-α (4.5-fold), while reducing GSH (57.6%), Nrf2 (77.7%), Sig1R (86.2%), D2R (64%), XIAP (77.8%), BDNF (57.6%) and SDH (61.44%) (all p < 0.0001). Treatment with ART (100 mg/kg) markedly restored behavioral performance, increasing rearing and ambulation by 3.2- and 2.6-fold, novel object exploration by 2.4-fold, and target quadrant time by 1.7-fold compared to the 3-NP group. At the molecular level, ART reduced HMGB1 (69.2%), TLR4 (60.4%), RIPK1 (66.3%), RIPK3 (66.4%), MLKL (58%), and TNF-α (62.5%), while significantly restoring GSH (2.1-fold), Nrf2 (3.7-fold), Sig1R (5.2-fold), D2R (2.6-fold), XIAP (3.7-fold), BDNF (2.3-fold) and SDH (1.94-fold) relative to 3-NP-treated rats. Collectively, these results demonstrate that ART confers robust neuroprotection against 3-NP-induced HD-like pathology by attenuating oxidative stress, suppressing HMGB1/TLR4/NF-κB signaling, inhibiting necroptosis, and upregulating neuroprotective markers. These findings highlight ART not only as a neuroprotective agent but also as a promising symptom-attenuating therapeutic candidate for Huntington's disease and other neurodegenerative disorders driven by oxidative and inflammatory stress.

Confidence: 0.31 · 15 полей извлечено
Идентификация (6 полей)
Target
Artemisinin
1.00
Alt. target
ART
1.00
Protein family
0.00
Functional class
0.00
Subcellular loc.
0.00
Isoforms (metab/obesity)
0.00
Механизм действия (21 полей)
Mechanism
Artemisinin attenuates neurodegeneration by modulating HMGB1/TLR4/NF-κB signaling, inhibiting necroptosis, reducing oxidative stress, and upregulating neuroprotective markers.
0.95
Mutations (obesity/lean)
0.00
Activity (obesity)
0.00
Activity temporal
0.00
Energy balance
0.00
Appetite
0.00
Fat metabolism
0.00
Lipolysis
0.00
Thermogenesis
0.00
Muscle metabolism
0.00
Inflammation
Artemisinin reduces inflammation by suppressing HMGB1/TLR4/NF-κB signaling and decreasing TNF-α.
0.90
Glucose metabolism
0.00
AA metabolism
0.00
Hormonal pathways
0.00
Cell death
Artemisinin inhibits necroptosis by reducing RIPK1, RIPK3, and MLKL levels.
0.90
Adipocyte fibrosis
0.00
Upstream (biochem)
3-nitropropionic acid (3-NP) upregulates HMGB1, TLR4, RIPK1, RIPK3, MLKL, p38-MAPK, NF-κB, TNF-α; downregulates GSH, Nrf2, Sig1R, D2R, XIAP, BDNF, SDH.
0.90
Upstream (physiol)
0.00
Downstream (biochem)
Artemisinin reduces HMGB1, TLR4, RIPK1, RIPK3, MLKL, TNF-α; restores GSH, Nrf2, Sig1R, D2R, XIAP, BDNF, SDH.
0.90
Downstream (physiol)
Artemisinin improves behavioral performance (rearing, ambulation, novel object exploration, Morris water maze target quadrant time).
0.90
PTMs
0.00
Экспрессия (8 полей)
Tissue expression
0.00
In vitro
0.00
In vivo
Rat model of Huntington's disease induced by 3-nitropropionic acid (3-NP). Artemisinin (100 mg/kg) treatment restored behavioral performance and modulated molecular markers.
0.95
In silico
0.00
Genetic association
0.00
Ex vivo
0.00
Animal model
Rat model of Huntington's disease induced by 3-nitropropionic acid (3-NP)
0.95
Diet/model
3-nitropropionic acid (3-NP) induced Huntington's disease model
0.95
Клиника (11 полей)
Drug
Artemisinin
1.00
Indication
Huntington's disease
1.00
Patient subgroups
0.00
Safety concerns
0.00
Off-target
0.00
Trial stage
Preclinical (rat model)
1.00
Pharma competitors
0.00
AE severity
0.00
MOA weight loss
0.00
Endpoints
0.00
Approved
False
0.90